Article
 

Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro

Public Deposited

Downloadable Content

Download PDF
https://ir.library.oregonstate.edu/concern/articles/qz20sv12s

Descriptions

Attribute NameValues
Creator
Abstract
  • Background: Canine oral fibrosarcoma (COF) is one of the most common oral tumors in dogs and carries a guarded prognosis due to a lack of effective systemic therapeutic options. Mastinib and imatinib are two commonly used tyrosine kinase inhibitors (TKIs) in veterinary oncology but their potential efficacy against COF is uncharacterized. To begin investigating the rationale for use of these TKIs against COF, the present study tested for the presence TKI targets PDGFR-α, PDGFR-β, Kit, and VEGFR-2 and examined the in vitro effects on cell viability after TKI treatment alone or with doxorubicin. Immunohistochemistry for PDGFR-α, PDGFR-β, Kit, and VEGFR-2 was performed in 6 COF tumor biopsies. Presence of these same receptors within 2 COF cell lines was probed by reverse transcription-polymerase chain reaction and, for those with mRNA detected, confirmed via western blot. Effects on cell viability were assessed using an MTS assay after masitinib or imatinib treatment alone (0-100 μM), or in combination with doxorubicin (0-3000 nM doxorubicin). Anti-PDGFRB siRNA knockdown was performed and the effect on cell viability quantified. Results: Expression of the TKI targets evaluated was similar between the 2 COF cell lines and the 6 COF tumor biopsies: PDGFR-α and PDGFR-β were detected in neoplastic cells from most COF tumor biopsies (5/6 and 6/6, respectively) and were present in both COF cell lines; KIT and KDR were not detected in any sample. Masitinib and imatinib IC50 values ranged from 7.9–33.4 μM, depending on the specific TKI and cell line tested. The addition of doxorubicin resulted in synergistic cytotoxicity with both TKIs. Anti-PDGFRB siRNA transfection reduced PDGFR-β protein expression by 77 % and 67 % and reduced cell viability by 24 % (p < 0.0001) and 28 % (0 = 0.0003) in the two cell lines, respectively. Conclusions: These results provide rationale for further investigation into the use of TKIs, possibly in combination with doxorubicin, as treatment options for COF.
  • Keywords: Masitinib, Oral fibrosarcoma, Imatinib, Platelet-derived growth factor receptor, Dog
Resource Type
DOI
Date Available
Date Issued
Citation
  • Milovancev, M., Helfand, S. C., Marley, K., Goodall, C. P., Löhr, C. V., & Bracha, S. (2016). Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Veterinary Research, 12, 85. doi:10.1186/s12917-016-0712-x
Journal Title
Journal Volume
  • 12
Rights Statement
Funding Statement (additional comments about funding)
  • This study was supported by intramural funding through Oregon State University's College of Veterinary Medicine Department of Clinical Sciences by provision of laboratory space and equipment to perform the study experiments.
Publisher
Peer Reviewed
Language
Replaces

Relationships

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details MilovancevAntiproliferativeEffectsofMasitini.pdf 2017-07-26 Public Download